Finland· FI-REL-REL64604
Rapiscan
A regadenoson product containing regadenoson, registered in Finland by Abacus Medicine A/S. The same ATC class is registered in 13 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Regadenoson is registered in 13 of 19 countries.
Countries holding a registration under ATC C01EB21 (regadenoson), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 9 of them publish a price we can compare per daily dose
Regadenoson · ATC C01EB21
13 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Fimea (Finland)- Active substance
- Regadenoson
- Manufacturer
- Abacus Medicine A/S
- Country
- Finland (FI)
- ATC code
- C01EB21
- ATC class
- Regadenoson
- Defined daily dose
- 0.4 mg, P
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
6 interactions on record for regadenoson.
Graded by severity as the source publishes them — 6 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Regadenoson · interactions on record
6 records
- 6 moderate
Most severe, free to view
- DipyridamoleB01AC07moderate
- DipyridamolC01DX29moderate
- TheophyllinC01EB28moderate
- CaffeineN06BC01moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Regadenoson in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- IrelandRapiscan 400 microgram solution for injectionGE Healthcare AS
- United StatesLEXISCANAstellas Pharma US, Inc.
- SwitzerlandRapiscan 400 µg/ 5 ml, InjektionslösungGE Healthcare AG
- CzechiaRAPISCANGE Healthcare AS, Oslo
- SpainRapiscan 400mcg solucion inyectableGe Healthcare As
- FranceRAPISCAN 400 microgrammes, solution injectableGE HEALTHCARE (NORVEGE)
- United KingdomRapiscan 400micrograms/5ml solution for injection vialsGE Healthcare Ltd
- BelgiumRapiscan 400 µgGE Healthcare
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Rapiscan
- Iceland · Rapiscan
- Liechtenstein · Rapiscan
- Norway · Rapiscan
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/8d7f7e00-9e98-4b86-b325-20142cd0cb36 GET /v1/drugs/8d7f7e00-9e98-4b86-b325-20142cd0cb36?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": "0.4",
"form": "injektioneste, liuos",
"route": "Laskimoon",
"ddd_unit": "mg",
"strength": "400 mikrog",
"atc_label": "regadenosoni",
"ma_number": null,
"auth_status": "Myyntilupa myönnetty",
"eu_ma_number": "EU/1/10/643/001",
"fimea_rel_id": "REL64604",
"authorised_at": "2025-08-22"
}See everything about regadenoson.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.